GERON CORP Inventory, Finished Goods, Net of Reserves
GERON CORP (GERN) had Inventory, Finished Goods, Net of Reserves of $17.46 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative › Inventory, Finished Goods and Work in Process, Net of Reserves
us-gaap:InventoryFinishedGoodsNetOfReserves · last filed 2026-08-05
- 2026-06-30: Inventory, Finished Goods, Net of Reserves $17.46M.
- 2026-03-31: Inventory, Finished Goods, Net of Reserves $18.57M.
- 2025-12-31: Inventory, Finished Goods, Net of Reserves $15.74M.
- 2025-09-30: Inventory, Finished Goods, Net of Reserves $18.41M.
| Period end | Inventory, Finished Goods, Net of Reserves |
|---|---|
| 2026-06-30 | $17.46M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $18.57M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $15.74M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $18.41M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $14.53M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $7.42M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $3.72M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |